Cargando…

Adjunction of a fish oil emulsion to cytarabine and daunorubicin induction chemotherapy in high-risk AML

The treatment of acute myeloid leukemia (AML) with unfavorable cytogenetics treatment remains a challenge. We previously established that ex vivo exposure of AML blasts to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or fish oil emulsion (FO) induces Nrf2 pathway activation, metabolic sw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gyan, Emmanuel, Pigneux, Arnaud, Hunault, Mathilde, Peterlin, Pierre, Carré, Martin, Bay, Jacques-Olivier, Bonmati, Caroline, Gallego-Hernanz, Maria-Pilar, Lioure, Bruno, Bertrand, Philippe, Vallet, Nicolas, Ternant, David, Darrouzain, François, Picou, Frédéric, Béné, Marie-Christine, Récher, Christian, Hérault, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192636/ https://www.ncbi.nlm.nih.gov/pubmed/35697729 http://dx.doi.org/10.1038/s41598-022-13626-y

Ejemplares similares

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment
por: Raut, Lalit S.
Publicado: (2015)

Occupational pesticide exposure increases risk of acute myeloid leukemia: a meta-analysis of case–control studies including 3,955 cases and 9,948 controls
por: Foucault, Amelie, et al.
Publicado: (2021)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high‐risk MDS: Phase 2 study results
por: Cortes, Jorge E., et al.
Publicado: (2018)

IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen
por: Libura, Marta, et al.
Publicado: (2021)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
por: Xie, Chengzhi, et al.
Publicado: (2013)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Cytarabine/daunorubicin: Coronavirus disease-2019 pneumonia: case report
Publicado: (2021)

Maintenance of elderly AML patients with androgens
por: Pigneux, Arnaud, et al.
Publicado: (2017)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Cerebral localization of chronic myelomonocytic leukemia and improvement with high‐dose cytarabine: A case report
por: Haméon, Clémence, et al.
Publicado: (2023)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Cytarabine/daunorubicin: Infections and flare-up of ulcer and cellulitis: 2 case reports
Publicado: (2022)

Automated Early Detection of Myelodysplastic Syndrome within the General Population Using the Research Parameters of Beckman–Coulter DxH 800 Hematology Analyzer
por: Ravalet, Noémie, et al.
Publicado: (2021)

Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin
por: Kulsoom, Bibi, et al.
Publicado: (2018)

Thrombotic Microangiopathy with Skin Localization Secondary to Cytarabine-Daunorubicin Association: Report of a Case
por: Regragui, S., et al.
Publicado: (2012)

Liposomal Daunorubicin and Cytarabine, a Potential Therapy for Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Ashok Kumar, Prashanth, et al.
Publicado: (2022)

Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial
por: Drevin, Guillaume, et al.
Publicado: (2022)

Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML
por: Malani, D, et al.
Publicado: (2017)

Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia
por: Wang, Jing, et al.
Publicado: (2013)

Disseminated Langerhans cell histiocytosis associated with acute myeloid leukaemia: complete remission with daunorubicin and cytarabine
por: Hwang, Yu-Yan, et al.
Publicado: (2012)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience
por: LaRochelle, Olivier, et al.
Publicado: (2011)

Low-Dose Pesticides Alter Primary Human Bone Marrow Mesenchymal Stem/Stromal Cells through ALDH2 Inhibition
por: Foucault, Amélie, et al.
Publicado: (2021)

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities()
por: Dennis, M., et al.
Publicado: (2013)

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties
por: Mayer, Lawrence D, et al.
Publicado: (2019)

Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study
por: van Eijkelenburg, Natasha K.A., et al.
Publicado: (2018)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
por: Fortin, Marie C., et al.
Publicado: (2023)

HOXA11 plays critical roles in disease progression and response to cytarabine in AML
por: Fu, Jen-Fen, et al.
Publicado: (2021)

Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes
por: Galtier, Jean, et al.
Publicado: (2021)

The role of VDR and BIM in potentiation of cytarabine–induced cell death in human AML blasts
por: Harrison, Jonathan S., et al.
Publicado: (2016)

Inhibition of FAO in AML co-cultured with BM adipocytes: mechanisms of survival and chemosensitization to cytarabine
por: Tabe, Yoko, et al.
Publicado: (2018)

The efficacy and safety of daunorubicin versus idarubicin combined with cytarabine for induction therapy in acute myeloid leukemia: A meta-analysis of randomized clinical trials
por: Wang, Hanyu, et al.
Publicado: (2020)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

Enhanced Amikacin Diffusion With Ultrasound and Microbubbles in a Mechanically Ventilated Condensed Lung Rabbit Model
por: Espitalier, Fabien, et al.
Publicado: (2020)

Daunorubicin, Cytarabine, and Cladribine Regimen Plus Radiotherapy and Donor Lymphocyte Infusion for Extramedullary Relapse of Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation
por: Sanna, Marco, et al.
Publicado: (2013)

Impact of FLT3-ITD location on cytarabine sensitivity in AML: a network-based approach
por: Pugliese, Giusj Monia, et al.
Publicado: (2023)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ahhavqd8qfvqd2kpi83776n5os